Holen Sie sich die Stockscreener-App
10.12
1.45%
0.145
Handel nachbörslich:
10.05
-0.075
-0.74%
Schlusskurs vom Vortag:
$9.98
Offen:
$10
24-Stunden-Volumen:
641.35K
Relative Volume:
1.52
Marktkapitalisierung:
$636.34M
Einnahmen:
$222.20K
Nettoeinkommen (Verlust:
$-168.02M
KGV:
-2.2442
EPS:
-4.5116
Netto-Cashflow:
$-152.10M
1W Leistung:
+6.80%
1M Leistung:
-12.41%
6M Leistung:
-50.34%
1J Leistung:
-36.68%
1-Tages-Spanne:
$9.92
$10.49
1-Wochen-Bereich:
$9.45
$10.49
52-Wochen-Spanne:
$8.63
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
Firmenname
Dbv Technologies Adr
Sektor
Branche
Telefon
33(0)155427878
Adresse
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
10.12 | 636.34M | 222.20K | -168.02M | -152.10M | -4.5116 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Eingeleitet | Guggenheim | Buy |
| 2025-05-29 | Fortgesetzt | Goldman | Sell |
| 2023-01-04 | Hochstufung | Societe Generale | Hold → Buy |
| 2022-12-16 | Herabstufung | Goldman | Neutral → Sell |
| 2022-05-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-09-14 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-01-22 | Herabstufung | Societe Generale | Hold → Sell |
| 2020-11-02 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-08-06 | Herabstufung | Societe Generale | Buy → Sell |
| 2020-08-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-17 | Herabstufung | Stifel | Buy → Hold |
| 2020-01-09 | Hochstufung | Stifel | Hold → Buy |
| 2019-12-16 | Eingeleitet | Citigroup | Buy |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-06-17 | Eingeleitet | Goldman | Buy |
| 2018-12-20 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-12-20 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | Herabstufung | Jefferies | Buy → Hold |
| 2018-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2017-10-31 | Hochstufung | Societe Generale | Sell → Hold |
| 2017-10-24 | Herabstufung | Societe Generale | Buy → Sell |
| 2017-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | Eingeleitet | Deutsche Bank | Buy |
| 2017-03-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2016-09-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-03 | Eingeleitet | Barclays | Overweight |
| 2015-10-23 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
DBV Technologies SA (DBV.HA) Stock Price, News, Quote & History - Yahoo! Finance Canada
DBV Technologies SA (DBV.HA) Interactive Stock Chart - Yahoo! Finance Canada
DBVT Q2 2026 Earnings: Wider-Than-Expected Loss Keeps the Focus on Pipeline ExecutionBanking Earnings Report - https://www.dars.gov.et/
DBV Technologies Submits FDA Biologics License Application for VIASKIN Peanut Patch in Children Ages 4-7 - Kalkine Media
DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans. - GlobeNewswire Inc.
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years - GlobeNewswire Inc.
DBVT Stock Price, Quote & News - Syfe
DBV Technologies S.A. (DBV.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada
DBVT Slides As DBV Technologies Leads Biotech ADR Losers - StocksToTrade
DBVT Slides As DBV Technologies Leads European Biotech Declines - timothysykes.com
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Eastern Progress
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
DBV Technologies to Participate in Upcoming September Investor Conferences - GlobeNewswire
A food-allergy treatment company will join three New York events in September - Stock Titan
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
DBV Technologies (DBVT) Edges Higher as Allergy Franchise Holds Above Key SupportATR Stop - dars.gov.et
DBV Technologies (DBVT) Edges Higher as Allergy Franchise Holds Above Key SupportMutual Fund Flow - siam.in
DBV Technologies (DBVT) Edges Higher as Allergy Franchise Holds Above Key SupportChannel Breakout - www.dars.gov.et
DBV Technologies (DBVT) Edges Higher as Allergy Franchise Holds Above Key SupportMomentum Stock Picks - www.dars.gov.et
DBV Technologies (DBVT) Edges Higher as Allergy Franchise Holds Above Key SupportBPI Bear Correction - dars.gov.et
DBV (DBVT) Quarterly Scorecard: The Bottom-Line Figure Trails Its Comparison at the Close; Market Reaction: Shares Move 2.14% Higher in the Latest ReadingEarnings Surprise Score - careplusvn.com
DBV (DBVT) Quarterly Scorecard: The Bottom-Line Figure Trails Its Comparison at the Close; Market Reaction: Shares Move 2.14% Higher in the Latest ReadingEarnings Quality Score - dars.gov.et
DBV (DBVT) Quarterly Scorecard: The Bottom-Line Figure Trails Its Comparison at the Close; Market Reaction: Shares Move 2.14% Higher in the Latest ReadingEarnings Beat Alert - dars.gov.et
DBV Technologies (NASDAQ:DBVT) Shares Up 6.2%Here's Why - MarketBeat
European ADRs Started The Week Slightly Higher In US Trading - Finimize
DBVT Q2 2026 Earnings: Wider-than-Expected Loss Reflects Pipeline Investment PressuresPost-Earnings Drift - careplusvn.com
MPM BioImpact LLC discloses 6.2% stake in DBV Technologies (DBVT) - Stock Titan
DBV technologies S.A. (ADR) (DBV1.SG) balance sheet - Yahoo Finance UK
DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4%Time to Buy? - MarketBeat
RA Capital discloses DBV Technologies (DBVT) 5.8% ownership via ADS holding - Stock Titan
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq - The Manila Times
DBV Technologies Announces Sale of Approximately $50 - GlobeNewswire
Form S-3ASR DBV TECHNOLOGIES S.A. For: 27 July By Investing.com - Investing.com Canada
Form S-3ASR DBV TECHNOLOGIES S.A. For: 27 July By Investing.com - Investing.com Nigeria
Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim - The Globe and Mail
Europe’s US-Listed ADRs Edged Higher Late Friday Morning - Finimize
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside (NASDAQ:DBVT) - Seeking Alpha
DBV Technologies on Track for Lowest Close Since December 2025 -- Data Talk - Moomoo
DBV Technologies stock falls on $150M share offering plan - Investing.com
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - The Manila Times
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - markets.businessinsider.com
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - GlobeNewswire
DBV Technologies S.A. - Via Ritzau
Cantor Fitzgerald reiterates Overweight on DBV Technologies stock - investing.com
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update - markets.businessinsider.com
DBV Technologies narrows Q2 loss, funds operations into Q3 2027 - scanx.trade
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report - markets.businessinsider.com
DBV Technologies (NASDAQ: DBVT) sees $174.9M cash and Q3 2027 runway - Stock Titan
DBV Technologies Announces the Filing of its 2026 Half-Year - GlobeNewswire
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update - The Manila Times
Finanzdaten der Dbv Technologies Adr-Aktie (DBVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dbv Technologies Adr-Aktie (DBVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Jan 29 '26 |
Sale |
4.86 |
534 |
2,595 |
144,995 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 18 '25 |
Sale |
4.19 |
1,292,103 |
5,413,912 |
7,303,369 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 17 '25 |
Sale |
4.85 |
2,076,990 |
10,070,232 |
8,595,472 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
| Mohideen Pharis | Chief Medical Officer |
Nov 20 '25 |
Sale |
2.88 |
6,496 |
18,708 |
103,153 |
5.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):